Pharma must improve existing methods to boost solubility as “quantum leap” unlikely

By Nick Taylor

- Last updated on GMT

To boost solubility pharma must develop, refine and improve existing methods as a “quantum leap” in formulation is unlikely, Pharmaterials' CEO said.

Interest in boosting bioavailability has risen as compounds coming through development pipelines have become less soluble. However, improvements to formulation are expected to be gradual.

I don’t think I have seen a dramatically new approach to this. We will develop them, refine, improve, but perhaps not [make] a quantum leap​”, Graham Buckton, CEO of Pharmaterials, a subsidiary of Pii, and professor at the London School of Pharmacy, told in-PharmaTechnologist.

Pharma companies are likely to be receptive to improved techniques. Buckton gave the example of amorphous formulations which were around for decades before being used frequently by industry.

It’s become acceptable out of necessity I imagine​”, Buckton said.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars